Sanofi: EC Approves Sarclisa SC For Multiple Myeloma, First EU Therapy Via On-Body Injector
(RTTNews) - The European Commission has approved Sarclisa (isatuximab) subcutaneous (SC) in combination with standard-of-care regimens for the treatment of patients with multiple myeloma (MM) across …
(RTTNews) - The European Commission has approved Sarclisa (isatuximab) subcutaneous (SC) in combination with standard-of-care regimens for the treatme
Read Full Story at Nasdaq News →Why This Matters
The EC’s approval of Sarclisa SC marks a pivotal shift in multiple myeloma treatment, offering patients a faster, less invasive alternative to intravenous infusion. Beyond convenience, this subcutaneous formulation could improve adherence and reduce healthcare system strain, setting a new standard for antibody-based therapies in oncology.
Background Context
Multiple myeloma, a relapsing blood cancer, has seen steady innovation, but delays in infusion-based treatments remain a barrier to optimal care. Sanofi’s subcutaneous version builds on the earlier IV approval, leveraging on-body injector technology to streamline dosing—a trend gaining traction in chronic disease management.
What Happens Next
Clinicians will likely prioritize patient preference when selecting between SC and IV formulations, while payers may assess cost-effectiveness. Observers should watch for real-world data on adherence and whether this approval accelerates similar subcutaneous formulations in other oncology indications.
Bigger Picture
This approval underscores the growing role of subcutaneous biologics in oncology, reducing clinic burden and aligning with value-based care models. It also reflects broader industry momentum toward patient-centric delivery systems, potentially reshaping treatment paradigms across hematologic malignancies.
